Ipca Laboratories Future Growth
Future criteria checks 4/6
Ipca Laboratories is forecast to grow earnings and revenue by 35.5% and 15.7% per annum respectively. EPS is expected to grow by 36.2% per annum. Return on equity is forecast to be 15.5% in 3 years.
Key information
35.5%
Earnings growth rate
36.2%
EPS growth rate
Pharmaceuticals earnings growth | 18.8% |
Revenue growth rate | 15.7% |
Future return on equity | 15.5% |
Analyst coverage | Good |
Last updated | 19 Apr 2024 |
Recent future growth updates
Recent updates
Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings
Feb 07Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Jan 09Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Aug 20Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet
Feb 28Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Sep 20Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)
Aug 31Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Jun 22Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)
May 28Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
Mar 15These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well
Sep 20Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
Aug 09Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
Jun 08How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?
Mar 26Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?
Mar 13Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently
Feb 28Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 23Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?
Feb 11Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?
Jan 30The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It
Jan 15Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly
Dec 31Don't Ignore The Fact That This Insider Just Sold Some Shares In Ipca Laboratories Limited (NSE:IPCALAB)
Dec 16The Case For Ipca Laboratories Limited (NSE:IPCALAB): Could It Be A Nice Addition To Your Dividend Portfolio?
Dec 13This Insider Has Just Sold Shares In Ipca Laboratories Limited (NSE:IPCALAB)
Nov 28Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
Nov 25Ipca Laboratories Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Nov 10Is Ipca Laboratories Limited's (NSE:IPCALAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Nov 08Do Insiders Own Lots Of Shares In Ipca Laboratories Limited (NSE:IPCALAB)?
Oct 24Ipca Laboratories' (NSE:IPCALAB) Wonderful 327% Share Price Increase Shows How Capitalism Can Build Wealth
Oct 09What We Learned About Ipca Laboratories' (NSE:IPCALAB) CEO Compensation
Sep 24Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2026 | 101,974 | 12,324 | 8,861 | N/A | 15 |
3/31/2025 | 89,007 | 9,519 | 6,705 | N/A | 16 |
3/31/2024 | 75,749 | 6,318 | -12,550 | N/A | 16 |
12/31/2023 | 71,875 | 5,643 | N/A | N/A | N/A |
9/30/2023 | 66,806 | 4,922 | 2,612 | 6,767 | N/A |
6/30/2023 | 62,500 | 4,911 | N/A | N/A | N/A |
3/31/2023 | 62,481 | 4,713 | 3,113 | 8,058 | N/A |
12/31/2022 | 60,225 | 5,250 | N/A | N/A | N/A |
9/30/2022 | 59,070 | 6,142 | 2,398 | 7,616 | N/A |
6/30/2022 | 58,505 | 7,205 | N/A | N/A | N/A |
3/31/2022 | 58,305 | 8,841 | 3,771 | 8,561 | N/A |
12/31/2021 | 56,561 | 9,152 | N/A | N/A | N/A |
9/30/2021 | 56,355 | 9,837 | 3,728 | 8,554 | N/A |
6/30/2021 | 54,521 | 10,005 | N/A | N/A | N/A |
3/31/2021 | 54,207 | 11,400 | 7,286 | 10,901 | N/A |
12/31/2020 | 53,802 | 10,647 | N/A | N/A | N/A |
9/30/2020 | 51,833 | 9,968 | 7,371 | 10,767 | N/A |
6/30/2020 | 51,061 | 9,228 | N/A | N/A | N/A |
3/31/2020 | 46,499 | 6,063 | 2,641 | 5,704 | N/A |
12/31/2019 | 44,563 | 6,189 | N/A | N/A | N/A |
9/30/2019 | 42,496 | 5,804 | 2,877 | 5,181 | N/A |
6/30/2019 | 39,777 | 5,059 | N/A | N/A | N/A |
3/31/2019 | 37,750 | 4,448 | 3,205 | 5,010 | N/A |
3/31/2018 | 32,852 | 2,394 | 2,044 | 3,411 | N/A |
3/31/2017 | 31,562 | 1,945 | N/A | 2,819 | N/A |
3/31/2016 | 28,671 | 931 | N/A | 7,087 | N/A |
3/31/2015 | 31,444 | 2,542 | N/A | 4,682 | N/A |
3/31/2014 | 32,818 | 4,785 | N/A | 5,223 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IPCALAB's forecast earnings growth (35.5% per year) is above the savings rate (6.7%).
Earnings vs Market: IPCALAB's earnings (35.5% per year) are forecast to grow faster than the Indian market (17.6% per year).
High Growth Earnings: IPCALAB's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: IPCALAB's revenue (15.7% per year) is forecast to grow faster than the Indian market (10% per year).
High Growth Revenue: IPCALAB's revenue (15.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IPCALAB's Return on Equity is forecast to be low in 3 years time (15.5%).